Castleark Management’s Guardant Health GH Stock Holding History

Castleark Management’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$14.8M	Sell	160,283 -4,760	-3%	-$478K	0.49%	41
2025 Q4	$16.9M	Buy	165,043 +4,970	+3%	+$445K	0.49%	39
2025 Q3	$10M	Buy	160,073 +38,513	+32%	+$2.1M	0.28%	64
2025 Q2	$6.33M	Buy	+121,560	New	+$5.43M	0.19%	101
2021 Q2	–	Sell	-13,898	Closed	-$2.12M	–	342
2021 Q1	$2.12M	Sell	13,898 -9,470	-41%	-$1.43M	0.08%	179
2020 Q4	$3.01M	Buy	+23,368	New	+$2.69M	0.11%	163
2019 Q4	–	Sell	-78,420	Closed	-$5.01M	–	368
2019 Q3	$5.01M	Sell	78,420 -80,779	-51%	-$7.12M	0.2%	148
2019 Q2	$13.7M	Buy	+159,199	New	+$12.2M	0.53%	43

Other funds holding GH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Castleark Management's GH Position: Q1 2026 in Review

Castleark Management reduced its Guardant Health (GH) stake by 2.9% in Q1 2026, selling an estimated $478K and leaving 160,283 shares worth $14.8M. The position accounts for 0.49% of the portfolio, ranked #41.

Castleark Management first reported a position in GH in Q2 2019 and has held it in 8 quarters since. The position peaked at $16.9M in Q4 2025. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

Castleark Management held 160,283 shares of Guardant Health worth $14.8M as of Q1 2026.
Castleark Management sold 4,760 Guardant Health shares in Q1 2026, an estimated $478K.
Guardant Health made up 0.49% of Castleark Management's portfolio in Q1 2026, its #41 holding.
Castleark Management first reported a position in Guardant Health in Q2 2019 and has held it in 8 quarters since.
Castleark Management's Guardant Health position peaked at $16.9M in Q4 2025.
481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Castleark Management's 13F filing for Q1 2026, filed 15 May 2026.